Last reviewed · How we verify
Nitroglycerin I
At a glance
| Generic name | Nitroglycerin I |
|---|---|
| Also known as | Tridil |
| Sponsor | Instituto de Cardiologia de Santa Catarina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia (NA)
- : Vascular Function in Health and Disease (PHASE1)
- The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns (NA)
- Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin (PHASE3)
- Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment (PHASE1, PHASE2)
- Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction (NA)
- A Cohort Prospective Study of Predictors Influencing the Quality of Visualization of the Operating Field During Orthognathic Surgery
- Letrozole as a Prophylaxis From GTN for Complete Mole Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitroglycerin I CI brief — competitive landscape report
- Nitroglycerin I updates RSS · CI watch RSS
- Instituto de Cardiologia de Santa Catarina portfolio CI